BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Reports

The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026

For three years the biotechnology industry waited for a turn. The first half of 2026 delivered one — and then several more in quick succession. In si...

June 29, 2026 | Analysis

Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next

For most of the last decade, the strategic case for running Asia-Pacific clinical trials could be summarised in a single word: China. A vast, treatment-n...

June 29, 2026 | Analysis

The Frontier That Won’t Quite Arrive

Ask the region’s clinical-operations leaders whether decentralised and hybrid trials are the future, and the answer is almost unanimous. Surveys keep...

June 26, 2026 | Analysis

Metabolon Delivers Landmark Metabolomics Dataset to Advance Rare Disease Research with Genomics England

Metabolon, Inc., the global leader in metabolomics solutions advancing life science research, diagnostics, therapeutics, and precision medicine, announced ...

June 26, 2026 | News

Vendor to Co-Innovator — or Bring It In-House? The CDMO Relationship Rewires

For two decades the contract development and manufacturing organisation occupied a comfortable, clearly understood place in the biopharma value chain. The ...

June 25, 2026 | Analysis

Security at What Cost? APAC and the Great Supply-Chain Reordering

For the better part of two decades, the global pharmaceutical supply chain ran on a simple, unsentimental bargain: make the chemistry where it is cheapest,...

June 24, 2026 | Analysis

Europe Greenlights BRAFTOVI, Cetuximab and FOLFOX Regimen for Previously Untreated BRAF-Mutant mCRC

uropean approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 de...

June 24, 2026 | News

Billions on Bioconjugation: Is APAC Building the Right ADC Capacity — or Too Much?

In Songdo, on the reclaimed waterfront west of Seoul, a 202,000-square-metre construction site is becoming the most expensive single statement Kore...

June 19, 2026 | Analysis

World-Class Plants, Who Will Run Them? APAC's Biomanufacturing Skills Gap

Walk into one of the gleaming new large-molecule plants going up across Songdo, Tuas or Hyderabad and the first impression is of inevitability. The...

June 18, 2026 | Analysis

Lilly's Jaypirca Combination Cuts Disease Progression Risk by 45% in Relapsed CLL Phase 3 Trial

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the...

June 16, 2026 | News

Elixiron Advances Precision Immunotherapy Strategy with Encouraging Alzheimer's Data

Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmun...

June 15, 2026 | News

Good Enough and Cheap, or Prove It's Equivalent? Asia's Biosimilar Trust Gap

There is a number that captures Asia's biosimilar paradox in a single line. According to Samsung Bioepis's quarterly tracking of the United States market, ...

June 15, 2026 | Analysis

Windward Bio Doses First Patients in Phase II COPD Trial of SKB378/WIN378

COPD study initiation expands SKB378/WIN378 development into a second major respiratory disease SKB378/WIN378 is currently being evaluated in the Phase ...

June 11, 2026 | News

Can the 'Pharmacy of the World' Survive Its Own Scandals?

In late September and early October 2025, children in the central Indian state of Madhya Pradesh began arriving at hospitals with the same grim trajectory:...

June 08, 2026 | Analysis

Stay Connected